Last reviewed · How we verify

Ahon Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Ahon Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo,Fulvestrant,Goserelin acetate Placebo,Fulvestrant,Goserelin acetate phase 3 Selective estrogen receptor degrader (SERD) + GnRH agonist combination Estrogen receptor (ER) + GnRH receptor Oncology
ET-26 ET-26 phase 3 SGLT2 inhibitor SGLT2 Diabetes
FCN-437c,Fulvestrant,Goserelin acetate FCN-437c,Fulvestrant,Goserelin acetate phase 3 Estrogen receptor degrader + GnRH agonist combination Estrogen receptor (ER); GnRH receptor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADvantage Therapeutics · 1 shared drug class
  2. AJU Pharm Co., Ltd. · 1 shared drug class
  3. AO GENERIUM · 1 shared drug class
  4. Abbott · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. Aciex Therapeutics, Inc. · 1 shared drug class
  8. 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ahon Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Ahon Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ahon-pharmaceutical-co-ltd. Accessed 2026-06-10.

Related